Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Standard

Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. / Nielsen, S D; Sørensen, A M; Schønning, Kristian; Lund, O; Nielsen, Jens Ole; Hansen, J E.

I: Scandinavian Journal of Infectious Diseases, Bind 29, Nr. 5, 1997, s. 447-452.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Harvard

Nielsen, SD, Sørensen, AM, Schønning, K, Lund, O, Nielsen, JO & Hansen, JE 1997, 'Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells.', Scandinavian Journal of Infectious Diseases, bind 29, nr. 5, s. 447-452. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9435030&query_hl=52>

APA

Nielsen, S. D., Sørensen, A. M., Schønning, K., Lund, O., Nielsen, J. O., & Hansen, J. E. (1997). Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. Scandinavian Journal of Infectious Diseases, 29(5), 447-452. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9435030&query_hl=52

Vancouver

Nielsen SD, Sørensen AM, Schønning K, Lund O, Nielsen JO, Hansen JE. Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. Scandinavian Journal of Infectious Diseases. 1997;29(5):447-452.

Author

Nielsen, S D ; Sørensen, A M ; Schønning, Kristian ; Lund, O ; Nielsen, Jens Ole ; Hansen, J E. / Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. I: Scandinavian Journal of Infectious Diseases. 1997 ; Bind 29, Nr. 5. s. 447-452.

Bibtex

@article{134c445f37764870a3ef8daaadfc992f,
title = "Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells.",
abstract = "We investigated if complement-mediated enhancement of HIV infection occurs in peripheral blood mononuclear cells (PBMC). In 7 experiments, we evaluated the effect of human complement on HIVIIIB infection in vitro. We measured HIV antigen production on day 4 and found that pre-incubation of HIV with complement led to enhanced production of antigen with a median enhancement of 2.5-fold (range 1.1-6.8). This complement-mediated increase in antigen production was statistically significant (p < 0.02). Complement-mediated enhancement of HIV infection was also tested in CD4 cells enriched from PBMC, and CD4 cells persistently gave higher levels of infection enhancement than PBMC. Thus, CD4 cells appear to be sufficient for complement-mediated enhancement of HIV infection to occur. In addition, we tested if it was possible to detect complement-mediated enhancement of primary HIV isolates in PBMC. We tested 3 isolates and found only a minor effect on antigen production (median enhancement 1.2-fold, range 0.6-1.5). Furthermore, addition of HIV-specific antibodies in combination with complement resulted in enhanced antigen production in 2/3 sera tested. However, the combination of complement and antibodies resulted in only a minor increase in enhancement of HIV infection compared to that obtained with complement alone. Finally, we found evidence of complement-mediated enhancement of HIV infection in resting PBMC. In conclusion, we demonstrated that complement-mediated enhancement of HIV infection does occur in vitro in PBMC.",
author = "Nielsen, {S D} and S{\o}rensen, {A M} and Kristian Sch{\o}nning and O Lund and Nielsen, {Jens Ole} and Hansen, {J E}",
year = "1997",
language = "English",
volume = "29",
pages = "447--452",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor & Francis",
number = "5",

}

RIS

TY - JOUR

T1 - Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells.

AU - Nielsen, S D

AU - Sørensen, A M

AU - Schønning, Kristian

AU - Lund, O

AU - Nielsen, Jens Ole

AU - Hansen, J E

PY - 1997

Y1 - 1997

N2 - We investigated if complement-mediated enhancement of HIV infection occurs in peripheral blood mononuclear cells (PBMC). In 7 experiments, we evaluated the effect of human complement on HIVIIIB infection in vitro. We measured HIV antigen production on day 4 and found that pre-incubation of HIV with complement led to enhanced production of antigen with a median enhancement of 2.5-fold (range 1.1-6.8). This complement-mediated increase in antigen production was statistically significant (p < 0.02). Complement-mediated enhancement of HIV infection was also tested in CD4 cells enriched from PBMC, and CD4 cells persistently gave higher levels of infection enhancement than PBMC. Thus, CD4 cells appear to be sufficient for complement-mediated enhancement of HIV infection to occur. In addition, we tested if it was possible to detect complement-mediated enhancement of primary HIV isolates in PBMC. We tested 3 isolates and found only a minor effect on antigen production (median enhancement 1.2-fold, range 0.6-1.5). Furthermore, addition of HIV-specific antibodies in combination with complement resulted in enhanced antigen production in 2/3 sera tested. However, the combination of complement and antibodies resulted in only a minor increase in enhancement of HIV infection compared to that obtained with complement alone. Finally, we found evidence of complement-mediated enhancement of HIV infection in resting PBMC. In conclusion, we demonstrated that complement-mediated enhancement of HIV infection does occur in vitro in PBMC.

AB - We investigated if complement-mediated enhancement of HIV infection occurs in peripheral blood mononuclear cells (PBMC). In 7 experiments, we evaluated the effect of human complement on HIVIIIB infection in vitro. We measured HIV antigen production on day 4 and found that pre-incubation of HIV with complement led to enhanced production of antigen with a median enhancement of 2.5-fold (range 1.1-6.8). This complement-mediated increase in antigen production was statistically significant (p < 0.02). Complement-mediated enhancement of HIV infection was also tested in CD4 cells enriched from PBMC, and CD4 cells persistently gave higher levels of infection enhancement than PBMC. Thus, CD4 cells appear to be sufficient for complement-mediated enhancement of HIV infection to occur. In addition, we tested if it was possible to detect complement-mediated enhancement of primary HIV isolates in PBMC. We tested 3 isolates and found only a minor effect on antigen production (median enhancement 1.2-fold, range 0.6-1.5). Furthermore, addition of HIV-specific antibodies in combination with complement resulted in enhanced antigen production in 2/3 sera tested. However, the combination of complement and antibodies resulted in only a minor increase in enhancement of HIV infection compared to that obtained with complement alone. Finally, we found evidence of complement-mediated enhancement of HIV infection in resting PBMC. In conclusion, we demonstrated that complement-mediated enhancement of HIV infection does occur in vitro in PBMC.

M3 - Journal article

VL - 29

SP - 447

EP - 452

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 5

ER -

ID: 34064753